Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS1 | P09382 | 2/20 | 0.47 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.47 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.47 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 5/20 | 0.42 |
| ▸ | CA1 | P00915 | 5/20 | 0.42 |
| ▸ | CA2 | P00918 | 5/20 | 0.42 |
| ▸ | CA9 | Q16790 | 5/20 | 0.42 |
| ▸ | PYGB | P11216 | 6/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | CA5A | P35218 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1035317 | 1.00 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| SCHEMBL15382611 | 1.00 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| SCHEMBL17993201 | 1.00 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| SCHEMBL22902769 | 1.00 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| SCHEMBL29055419 | 1.00 | LGALS1 (0.47) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| SCHEMBL15011450 | 0.98 | LGALS1 (0.43) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| SCHEMBL301532 | 0.98 | LGALS1 (0.43) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| SCHEMBL7155776 | 0.98 | LGALS1 (0.43) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| SCHEMBL7151021 | 0.98 | LGALS1 (0.43) | LGALS1LGALS3LGALS9LGALS8CA12 | |
| Water SCHEMBL29046820 | 0.96 | LGALS1 (0.42) | LGALS1LGALS3LGALS9LGALS8CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210401946-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2021-12-30 | — | — | US | disclosed |
| US-20210401947-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2021-12-30 | — | — | US | disclosed |
| US-11090364-B2 | Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein | SANOFI (FR) | 2021-08-17 | — | — | US | disclosed |
| US-20190209656-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | SANOFI (FR) | 2019-07-11 | — | — | US | disclosed |
| WO-2019115616-A1 | NOVEL 1,7-DICARBA-CLOSO-DODECABORANE(12) (META-CARBABORANE)-DERIVED CARBOXYLIC ACIDS SUITABLE FOR PEPTIDE MODIFICATION FOR APPLICATION IN BORON NEUTRON CAPTURE THERAPY (BNCT) | UNIVERSITÄT LEIPZIG (DE) | 2019-06-20 | — | — | WO | disclosed |
| EP-3463480-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | Sanofi (FR) | 2019-04-10 | — | — | EP | disclosed |
| EP-1551228-B1 | SYNTHETIC C-GLYCOLIPID AND ITS USE FOR TREATING CANCER INFECTIOUS DISEASES AND AUTOIMMUNE DISEASES | UNIV NEW YORK (US) | 2012-10-03 | — | — | EP | disclosed |
| US-8252909-B2 | Synthetic C-glycolipid and its use for treating cancer, infectious diseases, and autoimmune diseases | NEW YORK UNIVERSITY (US) | 2012-08-28 | — | — | US | disclosed |
| US-7273852-B2 | Synthetic C-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases | THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2007-09-25 | — | — | US | disclosed |
| US-20060019246-A1 | Synthetic C-glycolipid and its use for treating cancer, infectious diseases, and autoimmune diseases | NEW YORK UNIVERSITY (US) | 2006-01-26 | — | — | US | disclosed |
| EP-1551228-A2 | SYNTHETIC C-GLYCOLIPID AND ITS USE FOR TREATING CANCER INFECTIOUS DISEASES AND AUTOIMMUNE DISEASES | New York University (US) | 2005-07-13 | — | — | EP | disclosed |
| EP-1543019-A2 | MODIFIED PNA MOLECULES | Santaris Pharma A/S (DK) | 2005-06-22 | — | — | EP | disclosed |
| US-20040127429-A1 | Synthetic C-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK, THE | 2004-07-01 | — | — | US | disclosed |
| WO-2004024757-A2 | MODIFIED PNA MOLECULES | SANTARIS PHARMA A/S (DK) | 2004-03-25 | — | — | WO | disclosed |
| WO-2003105769-A2 | SYNTHETIC C-GLYCOLIPID AND ITS USE FOR TREATING CANCER INFECTIOUS DISEASES AND AUTOIMMUNE DISEASES | NEW YORK UNIVERSITY (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11090364-B2 | Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein | GPR119, SLC2A8, SLC2A4 | LGALS1 60/4885LGALS3 210/4885LGALS9 162/4885 |
| US-20190209656-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | GPR119, SLC2A8, SLC2A4 | LGALS1 60/4885LGALS3 210/4885LGALS9 162/4885 |
| US-20040127429-A1 | Synthetic C-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases | UGT8, UGCG, SGMS1 | LGALS1 495/4885LGALS3 786/4885LGALS9 835/4885 |
| US-20060019246-A1 | Synthetic C-glycolipid and its use for treating cancer, infectious diseases, and autoimmune diseases | CCR8, UGT8, H1-10 | LGALS1 1140/4885LGALS3 1288/4885LGALS9 1217/4885 |
| US-20210401946-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | GPR119, SLC2A8, SLC2A4 | LGALS1 60/4885LGALS3 210/4885LGALS9 162/4885 |
| US-20210401947-A1 | CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN | GPR119, SLC2A8, SLC2A4 | LGALS1 60/4885LGALS3 210/4885LGALS9 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.